Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades Provention Bio to Hold, Announces $25 Price Target

Jefferies analyst Chris Howerton downgrades Provention Bio (NASDAQ:PRVB) from Buy to Hold and announces $25 price target.

byBenzinga Newsdesk

March 14, 2023

1 minute read

Jefferies analyst Chris Howerton downgrades Provention Bio (NASDAQ:PRVB) from Buy to Hold and announces $25 price target.

Citigroup Maintains Buy on Grab Hldgs, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 4:57 PM

Citigroup analyst Alicia Yap maintains Grab Hldgs (NASDAQ:GRAB) with a Buy and lowers the price target from $5.4 to $5.

GRAB

Analyst Ratings

Analyst Ratings for Target

By Benzinga Insights

Today, 4:57 PM

Target (NYSE:TGT) has observed the following analyst ratings within the last quarter:

TGT

Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years

By Benzinga Insights

Today, 4:57 PM

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 20.68%. Currently, Boston Scientific has a market capitalization of $54.31 billion.

BSX

Natus Medical Q3 EPS $0.28 Misses $0.34 Estimate, Sales $113.90M Miss $116.80M Estimate

By Benzinga Newsdesk

Today, 4:57 PM

Natus Medical (NASDAQ:NTUS) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.34 by 17.65 percent. This is a 211.11 percent increase over earnings of $0.09 per share from

NTUS

Jefferies Downgrades Provention Bio to Hold, Announces $25 Price Target

Related Posts

Citigroup Maintains Buy on Grab Hldgs, Lowers Price Target to $5

Analyst Ratings for Target

Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years

Natus Medical Q3 EPS $0.28 Misses $0.34 Estimate, Sales $113.90M Miss $116.80M Estimate